Fortress Biotech is exiting 2025 and entering 2026 with a string of monetization events that reshape its balance sheet and operating model. The FDA approved Zycubo, a copper histidinate therapy for pediatric Menkes disease, and Cyprium Therapeutics, Fortress’s majority-owned subsidiary, sold the associated Rare Pediatric Disease Priority Review Voucher for $205 million. Separately, Sun Pharma acquired Fortress’s oncology subsidiary Checkpoint Therapeutics for roughly $355 million upfront plus a contingent value right, leaving Fortress with a 2.5% royalty on net sales of Unloxcyt in cutaneous squamous cell carcinoma. Meanwhile, Crystalys Therapeutics raised a $205 million Series A to run two Phase 3 trials of dotinurad for gout; Fortress’s Urica unit retains equity and a 3% royalty on future sales. Layered on top are the U.S. launch of Journey Medical’s Emrosi for rosacea and a markedly narrower annual net loss attributable to common shareholders, aided by reduced R&D spend and debt paydown following the PRV transaction.
The through-line is a deliberate pivot toward a capital recycling and royalty-driven engine. Fortress is converting development wins and corporate exits into upfront proceeds, milestone exposure, and recurring royalties while offloading a significant portion of clinical and commercial risk to partners. The strategic question is whether this diversified, partner-led structure can consistently out-earn dilution and market volatility better than a traditional single-pipeline biotech model.
This matters now because the PRV market remains one of the few reliable sources of large, non-dilutive capital in an uneven funding climate. A $205 million voucher sale underscores sustained sponsor demand to accelerate time-to-market, a signal that could influence how rare disease developers sequence registrational plans. For patients and HCPs, Zycubo’s approval moves Menkes disease from near-nihilistic outcomes toward an intervention that is likely most effective if initiated early, elevating the importance of newborn screening, diagnostic pathways, and Medical Affairs-led education to drive timely identification and initiation. For payers, rare pediatric therapies continue to test coverage frameworks; evidence generation strategies, including real-world data on functional outcomes and resource utilization, will be pivotal to support durable access.
Oncology and immunology peers should also note Sun Pharma’s U.S. expansion via Unloxcyt in cSCC, a maturing PD-(L)1 space where formulary positioning, community oncology penetration, and contracting could matter as much as head-to-head differentiation. Fortress’s royalty interest aligns its fortunes with how effectively Sun Pharma executes access and uptake against entrenched competitors. In parallel, dotinurad’s global Phase 3 move highlights renewed investment in urate transporter inhibition after earlier class setbacks, suggesting a bid to reset the standard of care in gout where suboptimal control and intolerance to xanthine oxidase inhibitors persist. Success here will hinge on clean safety, meaningful serum urate lowering, flare reduction, and compelling health-economic narratives in populations with cardiovascular and renal comorbidities.
Financially, Fortress is leaning into operating leverage. Lower internal R&D, growth in Journey’s dermatology revenues, and loan principal reduction improve optionality for business development while preserving exposure to upside through CVRs, sales milestones, and royalties from partners such as Sentynl, Sun Pharma, Axsome, and Crystalys. The model extends into neuromuscular disease with Avenue’s new license for a β2-adrenergic agonist in Pompe, another bet that external innovation and targeted development can be packaged into downstream economics.
The next test is execution outside Fortress’s walls. Can partner launches of Zycubo and Unloxcyt convert into steady royalty cash flows and validate the thesis that diversified, asset-light participation outperforms ownership in a high-cost capital cycle—or will payers’ evidentiary demands and competitive intensity compress those annuities faster than Fortress can replenish them?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
